线粒体靶向治疗在阿尔兹海默病中的研究进展

发布时间：2018-07-01 12:24

本文选题：阿尔兹海默病 + 线粒体　；参考：《重庆医科大学》2016年硕士论文

【摘要】：阿尔茨海默病(AD)是一种最常见的记忆和认知衰退的神经退行性疾病,影响了全世界数以百万计的人,而目前对于AD的病因仍不明确且临床上仍缺乏有效的治疗手段。线粒体是细胞的能量工厂,线粒体功能障碍在衰老进程中起到的作用已经被越来越多的研究证实,这些功能异常包括氧化应激诱导产生的呼吸链功能异常、线粒体动力学缺陷、线粒体生物发生受损、mtDNA的突变等,其在AD的病理过程中扮演重要的角色,可作为神经保护作用的药物治疗靶点,即通过保护和提高线粒体功能来达到延缓或改善患者的临床症状。本文主要阐释了线粒体功能障碍在AD的主要表现,并介绍了一系列具有相当前景的线粒体靶点治疗的药物和技术方法,为阿尔兹海默病的治疗提供了新的思路。
[Abstract]:Alzheimer's disease (AD) is one of the most common neurodegenerative diseases of memory and cognitive decline, affecting millions of people all over the world. Mitochondria are the energy factory of cells. The role of mitochondrial dysfunction in aging process has been confirmed by more and more studies. These abnormalities include respiratory chain dysfunction induced by oxidative stress and mitochondrial kinetic defects. Mitochondrial mutagenesis plays an important role in the pathological process of AD and can be used as a target of drug therapy for neuroprotective effect. That is by protecting and improving mitochondrial function to delay or improve the clinical symptoms of patients. This article mainly explains the main manifestation of mitochondrial dysfunction in AD, and introduces a series of promising drugs and technical methods of mitochondrial target therapy, which provides a new idea for the treatment of Alzheimer's disease.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R749.16

【相似文献】